Looking to leave Zolgensma data manipulation scandal behind, Brian Kaspar emerges at a new gene therapy player
A year after getting blamed by Novartis for a data manipulation scandal over its costly gene therapy Zolgensma, Brian Kaspar has turned up on the scientific advisory board of a new gene therapy player.
Kaspar and Thomas Dee, an old AveXis buddy, are taking board roles at Endsulin, a small biotech founded by longtime University of Wisconsin surgeon Hans Sollinger that’s searching for a better treatment for type 1 diabetes — one that doesn’t involve insulin jabs or a pancreas transplant.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.